RxDoctor Payments DataLook up a doctor →

James Patton, MD

Neurology · Asheville, NCNPI 1518945690

Payments from drug & device makers

$697,512in general payments, 2019–2025

Across 1,063 payments — averaging $656.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sage Therapeutics, LLC$497K
  • AbbVie$46K
  • Biogen$30K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$28K
  • EMD Serono, Inc.$24K
  • Bristol Myers Squibb$24K
  • plus $48K from 54 others

What the payments were for

  • Consulting fees$13,26210%
  • Speaking & faculty fees$94,97570%
  • Travel & lodging$8,6706%
  • Food & beverage$18,98114%
  • Education$2580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sage Therapeutics, LLC30$497,065
AbbVie(2 entities)194$46,066
Biogen89$29,658
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)9$28,461
EMD Serono, Inc.47$23,827
Bristol Myers Squibb14$23,590
Acorda Therapeutics, Inc35$17,791
Kyowa Kirin, Inc.11$9,685
Sanofi33$6,796
E.r. Squibb & Sons, L.L.C.9$1,639
MDD US Operations, LLC14$955
Teva Pharmaceuticals USA, Inc.30$827
UCB, Inc.27$682
Novartis41$672
Jazz Pharmaceuticals Inc.21$622
Amgen(2 entities)31$609
AstraZeneca(2 entities)29$567
Acadia Pharmaceuticals Inc18$396
Neurocrine Biosciences, Inc.17$386
Supernus Pharmaceuticals, Inc.18$372
Eisai Inc.19$370
SK Life Science, Inc.13$287
Catalyst Pharmaceuticals, Inc.13$287
Amneal Pharmaceuticals LLC16$271
Lilly USA, LLC16$266
Pfizer15$265
Neurelis, Inc.8$261
Sunovion Pharmaceuticals Inc.14$215
Avanir Pharmaceuticals, Inc.10$197
Merz Pharmaceuticals, LLC9$197
Greenwich Biosciences, Inc.11$196
Averitas Pharma Inc.9$190
Lundbeck LLC9$184
CSL Behring8$183
Johnson & Johnson(2 entities)8$171
Argenx US, Inc.7$167
Ipsen Biopharmaceuticals, Inc7$157
TG Therapeutics, Inc.7$156
Alnylam Pharmaceuticals Inc.6$153
Genentech USA, Inc.8$138
Tanabe Pharma America, Inc.6$132
Abbott7$118
Mallinckrodt Hospital Products Inc.4$109
Sumitomo Pharma America, Inc.6$102
Revance Therapeutics, Inc.3$96
Upsher-smith Laboratories LLC4$90
Scilex Pharmaceuticals Inc.4$89
Medtronic(2 entities)5$87
Otsuka America Pharmaceutical, Inc.4$87
Mallinckrodt Enterprises LLC5$86
Xeris Pharmaceuticals, Inc.4$86
Grifols USA, LLC5$77
Adamas Pharmaceuticals, Inc.4$76
ANI Pharmaceuticals, Inc.5$75
Biohaven Pharmaceuticals, Inc.5$74
Insightec,inc3$73
Cycle Pharmaceuticals Inc3$67
Vanda Pharmaceuticals Inc.3$62
Aquestive Therapeutics, Inc.3$56
Biohaven Pharmaceutical Holding Company Ltd.3$55

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$697,512 in reported general payments places this provider in the 90th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,648,076
Medicare patients
914
Services billed
113,014

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate46$276,008
BotoxOnabotulinumtoxina175$229,661
TysabriNatalizumab15$141,830
RytaryCarbidopa/Levodopa65$91,723
UbrelvyUbrogepant45$57,018
Nurtec OdtRimegepant Sulfate37$53,504
XeominIncobotulinumtoxina43$40,677
Carbidopa-LevodopaCarbidopa/Levodopa922$30,303
GablofenBaclofen21$21,156
Aimovig AutoinjectorErenumab-Aooe17$14,123
MyrbetriqMirabegron19$13,542
LyricaPregabalin15$12,390
Topiramate ErTopiramate14$11,754
Gabapentin483$9,667
Carbidopa-Levodopa ErCarbidopa/Levodopa153$9,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy$46,066$286,678220 claims
Acadia Pharmaceuticals IncNuplazid$396$276,00846 claims
BiogenTysabri$29,658$141,83015 claims
Amneal Pharmaceuticals LLCRytary$271$91,72365 claims
PfizerNurtec Odt, Lyrica$265$65,89352 claims
Upsher-smith Laboratories LLCTopiramate$90$1,365135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 566 neurology providers in North Carolina.

Other neurology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →